Keystone Symposia

Fairmont Banff Springs Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2014


Here are the related meetings in 2020:
HIV Pathogenesis and Cure (X6)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

HIV Pathogenesis - Virus vs. Host (X4)


Organizer(s) J. Victor Garcia-Martinez, Daria J. Hazuda and Dan R. Littman
March 9—14, 2014
Fairmont Banff Springs • Banff, AB Canada
Discounted Abstract Deadline: Nov 7, 2013
Abstract Deadline: Dec 11, 2013
Scholarship Deadline: Nov 7, 2013
Discounted Registration Deadline: Jan 10, 2014

Sponsored by Gilead Sciences, Inc. Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation


Summary of Meeting:
This meeting is focused on the latest breakthroughs in basic and translational HIV research with an emphasis on mechanistic models. It presents a detailed tour of all the key steps of virus replication from infection to AIDS. The program seamlessly incorporates key aspects of HIV biology including: 1) Virus entry/exit into/from the cell; 2) Entry into the host; 3) Virus-host genetics and co-evolution; 4) Virus-host interactions and responses; 5) Pathogenesis; 6) Reservoirs, latency and reactivation; and 7) HIV and the microbiome at the mucosa. Strong emphasis will be given to these and other areas well represented in the abstracts submitted. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on “HIV Vaccines: Adaptive Immunity and Beyond,” which shares opening and closing keynote addresses and two plenary sessions with this meeting.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, MARCH 9

16:00—20:00
Arrival and Registration

Van Horne Foyer
16:30—18:00
Keystone Symposia Webcast - HIV/AIDS: Strategies for an Endgame
Taped rebroadcast of the first virtual Keystone Symposia event. This can also be viewed online at any time at www.visualwebcaster.com/KSHIV.

Shaughnessy

MONDAY, MARCH 10

07:00—08:00
Breakfast

Mezzanine 2
08:00—09:00
Opening Addresses (Joint)

Van Horne Ballroom A/B
* Nicole Frahm, Bill & Melinda Gates Medical Research Institute, USA

* J. Victor Garcia-Martinez, University of North Carolina at Chapel Hill, USA

Myron S. Cohen, University of North Carolina at Chapel Hill, USA
Integrated HIV Prevention Strategies: High Time for a Synergistic Approach

Carl W. Dieffenbach, NIAID, National Institutes of Health, USA
The Big Questions: The Basic Research Progress Needed to Help Control the HIV/AIDS Pandemic

09:00—11:30
Portals of Entry and Sites of Dissemination (Joint)

Van Horne Ballroom A/B
* James A. Hoxie, University of Pennsylvania, USA

* Thomas Musich, 1Armed Forces Research Institute of Medical Sciences, Thailand

J. Victor Garcia-Martinez, University of North Carolina at Chapel Hill, USA
Mechanistic Analysis of Vaginal HIV Transmission and Prevention

Peter A. Anton, David Geffen School of Medicine at UCLA, USA
Rectal HIV Transmission

Ashley T. Haase, University of Minnesota, USA
Virus-Host Immune Interactions at the Portal of Entry and Vaccine Design to Prevent HIV-1 Transmission to Women

Thomas J. Hope, Northwestern University, USA
Short Talk: Hotspots of SIV Infection in the Female Reproductive Tract after Vaginal Exposure of Rhesus macaques to Single Round Dual Reporter Vector

Samuel K. Lai, University of North Carolina at Chapel Hill, USA
Short Talk: Influence of Vaginal Microbiota on the Diffusional Barrier Properties of Cervicovaginal Mucus against HIV

09:40—10:00
Coffee Break

Van Horne Foyer
11:30—13:00
Poster Setup

Mezzanine 2
13:00—22:00
Poster Viewing

Mezzanine 2
11:30—14:30
On Own for Lunch and Recreation

14:30—16:30
Workshop 1: Role of Animal Models for HIV Research

Van Horne Ballroom C
* Roberto F. Speck, University of Zurich, Switzerland

* Frank Kirchhoff, University of Ulm, Germany

Atef F. Allam, Walter Reed Institute of Research, USA
Characterization of B- and T Cells in the Gut Mucosa of Humanized DRAG Mice During HIV Infection

Timothy E. Dudek, Ragon Institute of MGH, MIT and Harvard, USA
Immunization of Humanized BLT Mice Against HIV Influences Early Immune Responses and Viral Loads

Yanhui Cai, Tulane National Primate Research Center, USA
SIV Infection of Lung Interstitial Macrophages Contributes to Tissue Damage and Inflammatory Responses in the Lung

Christopher A. Gaulke, University of California, Davis, USA
SIV Induced Disruption of microRNA Expression in the Small Intestine Contributes to Epithelial Barrier Dysfunction

Jung Joo Hong, KRIBB, South Korea
Early Lymphoid Responses and Germinal Center Formation Correlates with Lower Viral Load Set Points and Better Prognosis of SIV Infection

Luca Micci, Emory University, YNPRC, USA
Interleukin-21 Reduces Residual Immune Activation in ART-Suppressed SIV-Infected Rhesus macaques by Restoring Intestinal Th17 and Th22 Cells

M. Christine Zink, Johns Hopkins University, USA
Sustained Upregulation of Neurotoxic Kynurenine Pathway Metabolites in cART-Treated SIV-Infected Pigtailed Macaques: Impact on Neuroinflammation and Serotonin Metabolism

Adrienne E. Swanstrom, University of Pennsylvania, USA
In Vivo Evaluation of a Novel Variant of SIVmac Lacking CD4 Tropism

14:30—16:30
Workshop 1: Mucosal Immunity

Van Horne Ballroom A/B
* Marjorie Robert-Guroff, NCI, National Institutes of Health, USA

* Thomas J. Hope, Northwestern University, USA

Liang Shang, University of Minnesota, USA
Immune Complex – Fc Receptor Interactions Reduce Inflammatory Responses at the Genital Mucosa as a Correlate of SIV Vaccine-Induced Protection

Yichuan Wang, NCI, National institutes of Health, USA
Vaginal Type-II Mucosa Acts as an Inductive Site for the Generation of Primary CD8+ T Cell Mucosal Immune Responses

Genoveffa Franchini, NCI, National Institutes of Health, USA
Modulation of the RAS Pathways as a Biomarker of Protection Against HIV and as a Means to Improve Vaccine Efficacy

Rena D. Astronomo, Fred Hutchinson Cancer Research Center, USA
Neutrophils May Provide Front-Line Antibody Effector Functions in the Cervical But Not the Vaginal Mucosa

Béhazine Combadiere, Centre d'Immunologie et des Maladies Infectieuses, France
Cutaneous Routes for HIV Vaccination Strategies

Sampa Santra, Harvard Medical School, USA
Simian-Human Immunodeficiency Viruses with Transmitted/Founder Clade C HIV-1 Envelopes

Thorsten Demberg, NCI, National Institutes of Health, USA
Phenotyping and Characterization of Mucosal Memory B-Cell Populations in the SIV/SHIV Rhesus macaque Model

Thomas Musich, 1Armed Forces Research Institute of Medical Sciences, Thailand
Purification and Functional Characterization of Mucosal IgA from Vaccinated and SIV-Infected Rhesus macaques

15:30—17:00
Keystone Symposia Webcast - HIV/AIDS: Strategies for an Endgame
Taped rebroadcast of the first virtual Keystone Symposia event. This can also be viewed online at any time at www.visualwebcaster.com/KSHIV.

Shaughnessy
15:30—17:00
Keystone Symposia Webcast - HIV/AIDS: Strategies for an Endgame
Taped rebroadcast of the first virtual Keystone Symposia event. This can also be viewed online at any time at www.visualwebcaster.com/KSHIV.

Shaughnessy
16:30—17:00
Coffee Available

Van Horne Foyer
17:00—19:15
Host-Viral Co-Evolution

Van Horne Ballroom C
* Quentin J. Sattentau, Sir William Dunn School of Pathology, UK

* Doris Wilflingseder, Insbruck Medical University, Austria

Welkin E. Johnson, Boston College, USA
Genetic Barriers to Cross-Species Transmission and Emergence of Primate Immunodeficiency Viruses

Robert J. Gifford, University of Glasgow, UK
The Evolution and Emergence of Lentiviral Pandemics since the Neolithic Era

Viviana Simon, Icahn School of Medicine at Mount Sinai, USA
Short Talk: HIV Evolution in Humanized Mice

Li Wu, Ohio State University, USA
Short Talk: Identification of Cellular Proteins Interacting with the Retroviral Restriction Factor SAMHD1

Thijs Booiman, University of Amsterdam, Netherlands
Short Talk: The Effect of Genetic Variation in Trex1 on HIV-1 Disease Progression and in vitro HIV-1 Replication

Angelique Hoelzemer, Ragon Institute of MGH, MIT and Harvard, USA
Short Talk: Selection of a Distinct HIV-1 p24 Gag Sequence Polymorphism in KIR2DL3/HLA-C*03:04+ Individuals Is Associated with Viral Escape from Recognition by KIR2DL3+ NK Cells

17:00—19:15
Programming Durable Immunity

Van Horne Ballroom A/B
* Rafael Cubas, Vaccine and Gene Therapy Institute Florida, USA

* Hendrik Streeck, Military HIV Research Program, USA

Robert A. Seder, NIAID, National Institutes of Health, USA
Development of a Malaria Vaccine: A Parable of Vaccine Delivery, Breadth of Antigens and Effector Cells

Mark K. Slifka, Oregon National Primate Research Center, Oregon Health & Science University, USA
Potential Mechanisms for Sustaining Long-Term Humoral Immunity

Shane Crotty, La Jolla Institute for Immunology, USA
Tfh Cells and Memory Tfh Cells

Diego J. Farfán-Arribas, University of Massachusetts Medical School, USA
Short Talk: Evidence on the Involvement of Germinal Centers and T Follicular Helper Cells in DNA Immunization for HIV Vaccine Development

Ann J. Hessell, Oregon Health & Science University, USA
Short Talk: Cross-Clade Neutralizing Antibodies and Envelope-Specific TFH Cell Responses Are Elicited in Macaques Co-Immunized with DNA and Protein Env Vaccines Derived from Multiple Subjects during Development of Breadth

19:15—20:15
Social Hour with Lite Bites

Mezzanine 2
19:30—22:00
Poster Session 1

Mezzanine 2

TUESDAY, MARCH 11

07:00—08:00
Breakfast

Mezzanine 2
07:30—08:00
Poster Setup

Mezzanine 2
08:00—19:00
Poster Viewing

Mezzanine 2
08:00—11:15
Viral Entry/Exit and Host Genetics

Van Horne Ballroom C
* Eric Hunter, Emory University, USA

* Gilda Tachedjian, Burnet Institute, Australia

Wesley I. Sundquist, University of Utah School of Medicine, USA
HIV Assembly and Egress

Vineet N. KewalRamani, NCI, National Institutes of Health, USA
HIV Entry and Nuclear Translocation

Fadila Bouamr, NIAID, National Institutes of Health, USA
The Host and HIV Exit

Janice E. Clements, Johns Hopkins University, USA
Macrophages Contribute to the Latent Viral Reservoir in Tissues of cART Suppressed SIV-Infected Macaques

Peijun Zhang, University of Oxford, UK
Short Talk: Structural Mechanisms of HIV-1 Capsid Assembly and Maturation

Amy Hulme, Northwestern University, USA
Short Talk: Viral and Cellular Factors Affect HIV-1 Uncoating

08:00—11:00
Inducing Protective Immunity

Van Horne Ballroom A/B
* Anne-Sophie M. Dugast, Ragon Institute of MGH, MIT and Harvard, USA

* Adrian B. McDermott, National Institutes of Health, USA

William H. Robinson, Stanford University School of Medicine, USA
Protective B Cell Responses

Gabriel D. Victora, Rockefeller University, USA
Cellular Dynamics and Clonal Selection in the Germinal Center

Jonathan W. Yewdell, NIAID, National Institutes of Health, USA
Translating Information for MHC Class Immunosurveillance

Susan W. Barnett, Bill & Melinda Gates Foundation, USA
Non-Viral Delivery of Self-Amplifying mRNA: A Versatile Synthetic Vaccine Platform for HIV

Kelly D. Moynihan, Third Rock Ventures, USA
Short Talk: Lymph-Node Targeting of Molecular Vaccines through “Albumin Hitchhiking”

Joseph G. Jardine, The Scripps Research Institute, USA
Short Talk: Design of Germline-Targeted Immunogens with Enhanced Breadth for VRC01-Class Precursors

09:20—09:40
Coffee Break

Van Horne Foyer
11:15—12:00
Lunch

Mezzanine 2
12:00—14:30
Poster Session 2

Mezzanine 2
14:30—16:30
Panel 1: HIV/AIDS: Strategies for an Endgame (Joint)

Van Horne Ballroom A/B
* Carl W. Dieffenbach, NIAID, National Institutes of Health, USA

Galit Alter, Ragon Institute of MGH, MIT, and Harvard, USA

Peter A. Anton, David Geffen School of Medicine at UCLA, USA

Myron S. Cohen, University of North Carolina at Chapel Hill, USA

Magdalena E. Sobieszczyk, Columbia University, USA

David M. Margolis, University of North Carolina at Chapel Hill, USA

Thomas C. Quinn, NIAID and Johns Hopkins University, USA

16:30—17:00
Coffee Available

Van Horne Foyer
17:00—19:00
Mechanistic Models of Pathogenesis and Disease

Van Horne Ballroom C
* Heinrich Gottlinger, University of Massachusetts Medical School, USA

* Shokrollah Elahi, University of Alberta, Canada

Richard T. D'Aquila, Northwestern University, USA
APOBEC3s versus Vif-Positive HIV-1: Tipping the Balance toward Virus Control

Timothy W. Schacker, University of Minnesota, USA
The Natural History of HIV Infection in Lymphatic Tissues

Anthony L. Cunningham, Westmead Institute for Medical Research, Australia
Short Talk: HIV Inhibits Interferon Production in Macrophages and Dendritic Cells but Exerts Other Antiviral Mechanisms

Anna Aldovini, Boston Children's Hospital and Harvard Medical School, USA
Short Talk: HIV-1 Tat Engagement of Different Promoters in Different Cell Types Results in Apoptosis of CD4+ T Cells and Activation of ISG Linked to Immune Activation in Antigen Presenting Cells

17:00—19:15
Tackling Global HIV Diversity

Van Horne Ballroom A/B
* Richard A. Koup, NIAID, National Institutes of Health, USA

* Edward A. Berger, NIAID, National Institutes of Health, USA

Beatrice H. Hahn, University of Pennsylvania, USA
Phenotypic Properties of Transmitted Founder HIV-1

Bette Tina Marie Korber, Los Alamos National Laboratory, USA
Using Signatures of Neutralizing Antibodies to Inform Vaccine Design

Andrew B. Ward, The Scripps Research Institute, USA
High-Resolution Cryo-EM Studies of HIV-1 Env

Dan H. Barouch, Beth Israel Deaconess Medical Center, USA
Short Talk: Prospects for Monoclonal Antibody Therapy for HIV-1

Devin Sok, International AIDS Vaccine Initiative, USA
Short Talk: Promiscuous Glycan Site Recognition by Antibodies to the High-Mannose Patch of gp120 Facilitates Broader Neutralization of HIV

19:00
On Own for Dinner

Mezzanine 2

WEDNESDAY, MARCH 12

07:00—08:00
Breakfast

Mezzanine 2
08:00—11:15
Host-Virus Interactions and Responses

Van Horne Ballroom C
* Paul R. Clapham, University of Massachusetts Medical School, USA

* Jaisri R. Lingappa, University of Washington, USA

Michael Emerman, Fred Hutchinson Cancer Research Center, USA
How Ancient Host-Virus Interactions Shaped the Modern HIV-1 Pandemic in Humans

Theodora Hatziioannou, Aaron Diamond AIDS Research Center, USA
Restriction Factors and the Adaptation of HIV-1 to Non-Human Primates

Andrea Cimarelli, CIRI, International Center for Infectology Research, France
Exploring the Multiple Layers of Complexity Existing during the Early Phases of Infection of Myeloid Cells by Primate Lentiviruses

Reuben S. Harris, University of Minnesota, USA
Natural Resistance to HIV Infection by Select APOBEC3H Haplotypes

Daniel Claiborne, Ragon Institute of MGH, MIT, and Harvard, USA
Short Talk: Protective HLA Alleles Reduce Markers of Gut Damage and Microbial Translocation and Influence Early Inflammatory Cytokine Profiles

Rui Andre Raposo, George Washington University, USA
Short Talk: Increased Expression of Host Restriction Factors in HLA-B*57+ Individuals

08:00—11:15
Novel Mechanisms for Vaccine-Induced Protection

Van Horne Ballroom A/B
* Genoveffa Franchini, NCI, National Institutes of Health, USA

* Jeffrey Robert Schneider, Northwestern University, USA

Silke Paust, Baylor College of Medicine, USA
NK Memory to Experimental HIV Vaccines in Mice and Humanized Mice

Galit Alter, Ragon Institute of MGH, MIT, and Harvard, USA
Fc-Signatures of Functional HIV-Specific Antibodies

Penny L. Moore, University of the Witwatersrand and National Institute for Communicable Diseases, South Africa
Evolution of V1V2 Broad Neutralizing Antibodies during HIV-1 Infection

Louis J. Picker, Oregon Health & Science University, USA
Effector Memory T-Cell Targeted Vaccines

Susan Johnson, US Military HIV Research Program, USA
Short Talk: HIV-Specific Cytolytic CD4 T Cells Are Distinct from Th1 Cells and Preserved in HIV Infection

Anna Aldovini, Boston Children's Hospital and Harvard Medical School, USA
Short Talk: Resistance to Infection, Early and Persistent Suppression of SIVmac251 Viremia and Significant Reduction of Tissue Viral Burden after Mucosal Vaccination in Females Rhesus macaques

09:20—09:40
Coffee Break

Van Horne Foyer
11:15—12:45
Hands-On Computer Session on Los Alamos HIV Sequence Database
Maximum attendance: 60. Interested participants may sign up at the meeting on a first-come, first-serve basis.

Beatty
* Brian T. Foley, Los Alamos National Lab, USA

* Bette Tina Marie Korber, Los Alamos National Laboratory, USA

* Will Fischer, Los Alamos National Laboratory, USA

11:15—13:00
Poster Setup

Mezzanine 2
13:00—22:00
Poster Viewing

Mezzanine 2
12:45—14:30
On Own for Lunch and Recreation

14:30—16:30
Panel 2: Functions of Protective Antibodies

Van Horne Ballroom A/B
Stephen J. Kent, University of Melbourne, Australia

Margaret E. Ackerman, Dartmouth College, USA

Nancy L. Haigwood, Oregon Health & Science University, USA

Ruth M. Ruprecht, Texas Biomedical Research Institute, USA

James Arthos, NIAID, National Institutes of Health, USA

* Susan Zolla-Pazner, Icahn School of Medicine at Mount Sinai, USA

14:30—16:30
Workshop 2: It Is All in the Head: HIV, Macs, DCs and the CNS

Van Horne Ballroom C
* Brenda L. Fredericksen, NIAID, National Institutes of Health, USA

* Pamela J. Skinner, University of Minnesota, USA

Joe Casazza, NIAID, National Institutes of Health, USA
Identification of HIV-Infected CD4+ T Cells using HIV RNA and Broadly Neutralizing Antibodies

Andrew N. Harman, Westmead Institute, Australia
The Role of Mucosal Dendritic Cells in HIV Infection

Rosa Camacho, Instituto Nacional de Enfermedades Respiratorias, Mexico
TNFalpha Overproduction by Conventional Dendritic Cells in Viremic versus Controller HIV Subjects

Alexandre Deshiere, Laval University, Canada
Transcriptomic and Proteomic Screening of Host Genes Modulated by HIV-1 in Human Macrophages: A Highly Sensitive Strategy for the Identification of New Susceptibility/Restriction Factors

Katharina Borm, Burnet Institute, Australia
Envelope Glycoprotein Determinants of Macrophages Tropism during Progressive HIV-1 Subtype C Infection

Maria Paz Gonzalez-Perez, UMASS, USA
HIV-1 R5 Envelopes from Brain and Immune Tissue of AIDS Patients with Normal Neurology are Less Functional and Less Macrophage-Tropic Compared to those in HAD Patients

Sheila M. Keating, GigaGen, USA
Cerebrospinal Fluid and Blood Inflammatory Biomarkers are Differentially Elevated in HIV and Neurological Disease

David R. Graham, Johns Hopkins School of Medicine, USA
A Combined Proteomics and Metabolomics Study of CSF from HAND Patients Under cART Therapy Reveals Evidence for Ongoing Macrophage Activation and Pertubations in Glutamate Metabolism

15:30—17:00
Keystone Symposia Webcast - HIV/AIDS: Strategies for an Endgame
Taped rebroadcast of the first virtual Keystone Symposia event. This can also be viewed online at any time at www.visualwebcaster.com/KSHIV.

Shaughnessy
16:30—17:00
Coffee Available

Van Horne Foyer
17:00—19:15
HIV, the Microbiome and the Mucosa

Van Horne Ballroom C
* Charles R. Rinaldo, University of Pittsburgh, USA

* John C. Tilton, Case Western Reserve University, USA

Dan R. Littman, HHMI/New York University School of Medicine, USA
Immue Homeostasis and Commensal Bacteria

Nichole R. Klatt, University of Miami, USA
Kinetics of Mucosal Dysfunction after SIV Infection of Rhesus macaques

Satya Dandekar, University of California, Davis, USA
HIV Pathogenesis: The GALT

Brent E. Palmer, University of Colorado Health Sciences Center, USA
Short Talk: Alterations in the Gut Microbiota Associated with HIV Infection

Hannah J. Barbian, University of Pennsylvania, USA
Short Talk: Evaluating the Enteric Virome as a Marker of Disease Progression in SIVcpz Infected Wild-Living Chimpanzees

17:00—19:15
Engineering Protective Immune Responses

Van Horne Ballroom A/B
* Rena D. Astronomo, Fred Hutchinson Cancer Research Center, USA

* Mark Connors, NIAID, National Institutes of Health, USA

William Schief, International AIDS Vaccine Initiative and The Scripps Research Institute, USA
Vaccines to Induce Broadly Neutralizing Antibodies

Nicholas M. Valiante, Novartis Vaccines and Diagnostics, USA
Minimal Essential Adjuvants: A Rational Approach for Optimizing Small Molecules as Vaccine Adjuvants

Mario Roederer, NIAID, National Institutes of Health, USA
Antigenic Heterogeneity of Clonal Envelopes: A Novel Immune Evasion Mechanism

Louise Scharf, California Institute of Technology, USA
Short Talk: A New Site of Broad Vulnerability on the HIV-1 Envelope Spike Defined by a Patient-Derived Antibody

19:15—20:15
Social Hour with Lite Bites

Mezzanine 2
19:30—22:00
Poster Session 3

Mezzanine 2

THURSDAY, MARCH 13

07:00—08:00
Breakfast

Mezzanine 2
08:00—11:15
Reservoirs, Latency, Reactivation and Eradication

Van Horne Ballroom C
* Robert W. Buckheit, Jr., ImQuest BioSciences, Inc., USA

* Linda Chelico, University of Saskatchewan, Canada

Daria J. Hazuda, Merck Research Laboratories, USA
New Drug Targets in the Search for an HIV Cure

David M. Margolis, University of North Carolina at Chapel Hill, USA
HIV Eradication Approaches

Hiroyu Hatano, University of California, San Francisco, USA
HIV Persistence in "Elite" Controllers

Steven Wolinsky, Northwestern University, USA
Persistent HIV-1 Replication and Evolution in Drug Sanctuaries within Peripheral Lymphoid Organ Compartments in Patients on Combination Antiretroviral Therapy

Edward A. Berger, NIAID, National Institutes of Health, USA
Short Talk: Novel CD4-Based Chimeric Antigen Receptors: Toward an HIV Functional Cure Using Genetically Modified CD8+ T Cells

Scott G. Kitchen, University of California, Los Angeles AIDS Institute, USA
Short Talk: Engineering Stem Cells with Chimeric Antigen Receptors for HIV-Specific T Cell Immunity

08:00—11:15
From Concepts to Implementation

Van Horne Ballroom A/B
* Liang Shang, University of Minnesota, USA

* William A. Paxton, Institute of Infection and Global Health, UK

Nicole Frahm, Bill & Melinda Gates Medical Research Institute, USA
Immunogenicity of HIV Vaccine Candidates in the HIV Vaccine Trials Network (HVTN)

Magdalena E. Sobieszczyk, Columbia University, USA
Lessons from HVTN 505 Efficacy Trial of a DNA/rAd5 HIV Preventive Vaccine

Jerome H. Kim, International Vaccine Institute, South Korea
RV144 and HIV Acquisition: Insights and New Questions

Thomas C. Quinn, NIAID and Johns Hopkins University, USA
The Impact of Combination Prevention on the HIV Pandemic

Susan Zolla-Pazner, Icahn School of Medicine at Mount Sinai, USA
Short Talk: IgG V3-Specific Antibody (Ab) Reactivity in Plasma from RV144: Implications for Vaccine Efficacy

Iskra Tuero, Universidad Peruana Cayetano Heredia, Peru
Short Talk: SIV Trimeric versus Monomeric Env-Induced Antibodies and Delayed SIV Acquisition in Vaccinated Female Rhesus macaques

09:20—09:40
Coffee Break

Van Horne Foyer
11:15—12:45
Hands-On Computer Session on Los Alamos HIV Immunology Database
Maximum attendance: 60. Interested participants may sign up at the meeting on a first-come, first-serve basis.

Beatty
* Brian T. Foley, Los Alamos National Lab, USA

* Bette Tina Marie Korber, Los Alamos National Laboratory, USA

* Will Fischer, Los Alamos National Laboratory, USA

12:45—15:30
On Own for Lunch and Recreation

14:30—16:30
Panel 3: Triggering Protective B-Cell Responses

Van Horne Ballroom A/B
* George K. Lewis, University of Maryland, USA

M. Anthony Moody, Duke University Medical Center, USA

Rogier W. Sanders, University of Amsterdam and Weill Cornell Medical College, Netherlands
Neutralizing Antibodies Induced by a Soluble Cleaved HIV Envelope Trimer, BG505 SOSIP.664 gp140

Jens P. Wrammert, Emory University, USA
Interrogating SIV/HIV Specific Plasmablast Responses in Rhesus macaques

Alejandro Balazs, Massachusetts General Hospital, USA

Burton E. Barnett, Genomics Institute of the Novartis Research Foundation, USA

15:30—17:00
Keystone Symposia Webcast - HIV/AIDS: Strategies for an Endgame
Taped rebroadcast of the first virtual Keystone Symposia event. This can also be viewed online at any time at www.visualwebcaster.com/KSHIV.

Shaughnessy
16:30—17:00
Coffee Available

Van Horne Foyer
17:00—18:45
Cellular and Genetic Therapies for HIV/AIDS (Joint)

Van Horne Ballroom A/B
* Nicole Frahm, Bill & Melinda Gates Medical Research Institute, USA

* J. Victor Garcia-Martinez, University of North Carolina at Chapel Hill, USA

Robert F. Siliciano, Johns Hopkins University School of Medicine, USA
Prospects for HIV Eradication

Nicolas Chomont, Université de Montréal, Canada
HIV Persistence during ART: What Can We Learn from CD4 T Cell Homeostasis?

Jerome A. Zack, University of California, Los Angeles, USA
Novel Means for Eliminating Latent HIV Reservoirs

18:45—19:30
Keynote Address (Joint)

Van Horne Ballroom A/B
Mark M. Davis, Stanford University School of Medicine, USA

19:30—20:30
Social Hour with Lite Bites

Mezzanine 2
20:00—23:00
Entertainment

Mezzanine 2

FRIDAY, MARCH 14

 
Departure


*Session Chair †Invited, not yet responded.


Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:

Bill & Melinda Gates Foundation Gilead Sciences, Inc.

We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13AI110242-01

The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We gratefully acknowledge additional support for this conference from:

Canadian HIV Vaccine Initiative Research & Development Alliance

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

S. Karger AG - Intervirology

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations

If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Corporate Relations, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org,
Phone:+1 970-262-1179